US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

ホーム
投資
株式
アメリカ
USOTC
Revive Therapeutics Ltd (QB) (RVVTF)
Revive Therapeutics Ltd (QB) (RVVTF) ニュース

RVVTF

Revive Therapeutics (QB) (RVVTF)

Revive Therapeutics Ltd (QB)

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:USOTC:RVVTF

日付	受信時刻	ニュースソース	見出し	コード	企業名
2022/04/18	23 : 26	InvestorsHub NewsWire	Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2022/04/12	21 : 00	InvestorsHub NewsWire	Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2022/03/29	22 : 57	InvestorsHub NewsWire	Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2022/02/24	22 : 35	InvestorsHub NewsWire	HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2022/02/16	22 : 03	InvestorsHub NewsWire	Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2022/02/14	20 : 53	InvestorsHub NewsWire	Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2022/01/19	22 : 19	InvestorsHub NewsWire	Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2022/01/17	23 : 13	InvestorsHub NewsWire	Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2022/01/07	22 : 05	InvestorsHub NewsWire	Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/11/16	22 : 00	InvestorsHub NewsWire	Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/09/22	20 : 30	InvestorsHub NewsWire	Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/08/18	19 : 00	InvestorsHub NewsWire	Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/08/12	22 : 56	InvestorsHub NewsWire	Revive Confirms No Material Undisclosed Information	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/08/10	21 : 52	InvestorsHub NewsWire	Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/07/16	03 : 47	InvestorsHub NewsWire	Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trialfor Bucillamine in COVID-19	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/06/28	21 : 00	InvestorsHub NewsWire	Revive Therapeutics Approved to Trade on the OTCQB Market	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/06/17	21 : 59	InvestorsHub NewsWire	Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/06/08	22 : 12	InvestorsHub NewsWire	Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/05/17	22 : 48	InvestorsHub NewsWire	Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/05/03	22 : 32	InvestorsHub NewsWire	Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/04/27	22 : 51	InvestorsHub NewsWire	Revive Therapeutics Files For FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/04/22	21 : 26	InvestorsHub NewsWire	Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....cont	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/03/24	22 : 15	InvestorsHub NewsWire	Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/03/19	20 : 56	InvestorsHub NewsWire	Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of ...Cont	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/02/26	23 : 01	InvestorsHub NewsWire	Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...Cont	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/02/26	23 : 01	InvestorsHub NewsWire	Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...Cont	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/02/17	23 : 53	InvestorsHub NewsWire	Revive Therapeutics Acquires Unique Psilocybin Assets	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/02/11	22 : 05	InvestorsHub NewsWire	Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/01/27	22 : 13	InvestorsHub NewsWire	Revive Therapeutics in Phase 3 clinical trial for COVID-19 treatment	USOTC:RVVTF	Revive Therapeutics Ltd (QB)
2021/01/18	23 : 51	InvestorsHub NewsWire	How Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain Injuries	USOTC:RVVTF	Revive Therapeutics Ltd (QB)

Showing the most relevant articles for your search:USOTC:RVVTF

Financial Select Sector

US Dollar vs Yen

Gold vs US Dollar

Bank of America

Energy Select Sector SPDR

Deutsche Telekom (QX)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約